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Abstract
Computational docking as a means to prioritise small molecules in drug discovery projects remains 
a highly popular in silico screening approach. Contemporary docking approaches without 
experimental parametrisation can reliably differentiate active and inactive chemotypes in a protein 
binding site, but the absence of a correlation between the score of a predicted binding pose and the 
biological activity of the molecule presents a clear limitation.
Several novel or improved computational approaches have been developed in the recent past to aid 
in screening and profiling of small-molecule ligands for drug discovery, but also more broadly in 
developing conceptual relationships between different protein targets by chemical probing. Among 
those new methodologies is a strategy known as inverse virtual screening, which involves the 
docking of a compound into different protein structures. In the present article, we review the 
different computational screening methodologies that employ docking of atomic models, and, by 
means of a case study, present an approach that expands the inverse virtual screening concept.
By computationally screening a reasonably sized library of 1235 compounds against a panel of 48 
mostly human kinases, we have been able to identify five groups of putative lead compounds with 
substantial diversity when compared to each other. One representative of each of the five groups 
was synthesised, and tested in kinase inhibition assays, yielding two compounds with micro-molar 
inhibition in five human kinases. 
This highly economic and cost-effective methodology holds great promise for drug discovery 
projects, especially in cases where a group of target proteins share high structural similarity in their 
binding sites. 
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1. Introduction
Because of the increasing importance placed on the pursuit of innovative chemical starting points 
(leads) in contemporary small-molecule drug discovery (Leeson & Springthorpe, 2007; Oprea, 
2002), the challenge to identify non-promiscuous kinase inhibitors is made even more daunting on 
account of the limited number of known chemotypes. The search for new lead structures in 
contemporary drug discovery typically entails the high-throughput screening of megalibraries of 
small organic molecules (molecules with a molecular mass <500 Da) against modified cell lines or 
isolated recombinantly produced target proteins to identify novel modulators (Macarron et al., 
2011).  While in the field of protein kinases, for example, many ATP-competitive inhibitors were 
indeed discovered via this strategy, high-throughput screening has lost much of its initial 
momentum as most of the scaffolds present in existing libraries have now been identified (Li et al., 
2004). Another limitation associated with the high-throughput screening of compound libraries 
(especially against a comprehensive panel of protein kinases) is that the process can be time and 
resource intensive (Camp et al., 2012). Because of these drawbacks, predictive methods have 
increasingly been employed to identify new modulators that could potentially be developed into 
drugs. 
In the past 15 years, a variety of different informatics-based and computational methods have been 
developed to aid in screening and profiling of small-molecule ligands for drug discovery (for a 
review see (Ekins et al., 2007)). A relatively new strategy known as inverse virtual screening (IVS) 
involves the docking of a compound into different protein structures described in protein databases 
(Chen & Zhi, 2001; Hui-fang et al., 2010; Lauro et al., 2011; Paul et al., 2004). Here, we present a 
brief overview of the different computational screening methodologies based on docking, and show 
that the resulting “panel docking”  scores potentially facilitate the identification and analysis of 
promising modulators through statistical analysis of predicted binding to more than one target 
protein.
2. Background
2.1 Kinase drug discovery
Currently, just over 500 protein kinases have been identified in the human genome (Zhang et al., 
2009).  Kinases play crucial roles in the regulation of a wide range of cellular processes, including 
cell-cycle progression, transcription, DNA replication and metabolic functions by catalysing the 
transfer of phosphates to serine, threonine and tyrosine residues (Hanks et al., 1988). Most protein 
kinases possess a catalytic domain, which binds and phosphorylates target proteins, as well as a 
regulatory region, which, in turn, may be regulated by (auto)phosphorylation. The dysregulation of 
kinase function has established protein kinases as drug targets in cancer (e.g. Imatinib/Gleevec 
targeting BCR-Abl tyrosine kinase, c-Kit receptor tyrosine kinase, PDGF receptor) and, more 
recently, inflammatory diseases such as  rheumatoid arthritis and myelofibrosis (e.g. Janus kinase 
inhibitors Tofacitinib and Ruxolitinib) (Cohen & Alessi, 2013). However, despite their 
attractiveness as drug targets, their relatively conserved ATP binding site presents a significant 
challenge in the discovery of non-promiscuous inhibitors. Structurally, the catalytic domains of 
eukaryotic protein kinases (Figure 1) share a highly conserved bilobal fold with 12 characteristic 
structural features (also known as subdomains and denoted with Roman numerals) (Hanks & 
Hunter, 1995). Given that the nucleotide binding sites of kinases are the most prominent, but also 
most highly conserved, druggable sites, two major challenges become crucial for drug discovery: (i) 
how can compounds be developed that selectively bind to a specific nucleotide binding site rather 
than any of the other >500 kinases, and; (ii) the newly developed compounds need to compete with 
ATP concentrations at the millimolar level and thus possess very high potency to be effective as a 
drug. The combination of selectivity and potency poses a serious challenge, but recent examples 
(see above) show that effective compounds can be developed. Intriguingly, in some therapeutic 
areas high specificity may not actually be required. One such example is Imatinib (Gleevec) where 
its broad range of efficacy is not undesired in the field of oncology (Cohen & Alessi, 2013).
2.2 Ligand-protein docking and the virtual screening approach
The concept of ligand-protein docking is widely used and has generally been proven to be a useful 
tool in aiding drug development. The fundamental process of docking comprises placement of a 
single small-molecule ligand in a pre-defined protein binding site. The binding pose of the placed 
ligand in a single, but more frequently in multiple conformations is evaluated by means of a scoring 
function. A variety of different algorithms have been established, and include shape matching 
(Kuntz et al., 1982; Miller et al., 1994), fragment-based docking (Böhm, 1992; Eisen et al., 1994; 
Ewing et al., 2001; Schellhammer & Rarey, 2004; Welch et al., 1996), simulated annealing (Morris 
et al., 2009), as well as genetic algorithms (Jones et al., 1997; Oshiro et al., 1995), evolutionary 
programming (Gehlhaar et al., 1995), and other approaches (Baxter et al., 1998; Blom & Sygusch, 
1997; Lorber & Shoichet, 2005; McMartin & Bohacek, 1997; Wang et al., 1999). A detailed 
assessment of different docking programs and their scoring functions revealed that these approaches 
work well as an overall methodology, but the binding pose observed in the experimental crystal 
structure is often not identified by the scoring functions, albeit the pose is reproduced as one of 
many by the docking algorithm (Warren et al., 2006). Accordingly, the scores achieved in ligand-
protein docking are poor indicators of affinity.
The availability of established algorithms and the high degree of automation paired with the 
substantial computing power of modern processors has made automated ligand-protein docking a 
frequently used tool for virtual screening. In this process, the binding mode  of a large number of 
small-molecule ligands with a single target protein can be evaluated in a fairly short time period. 
Two fundamental parameters characterise the performance of a virtual screening protocol (Warren 
et al., 2006): (i) the enrichment, which expresses the chance of identifying an active compound as 
compared to pure random choice, and (ii) the lead identification, which informs about how many 
compounds need to be screened until at least one representative of each active compound class has 
been identified.
2.3 The inverse virtual screening approach
In contrast to conventional virtual screening, which employs a single protein target and a library of 
small-molecule ligands, this situation is turned around in the inverse virtual screening approach. 
Conceptually, a single small-molecule ligand is docked into a variety of different protein targets. 
Inverse virtual screening has received some attention in the recent past due to its potential for 
identification of new target proteins for a given natural product. This methodology is based on the 
fact that proteins adopt a finite number of folds (~10,000) (Koonin et al., 2002) and that the 
recognition of any natural small-molecule ligand is coded into the particular protein fold by means 
of the three-dimensional conformations of the small-molecule as well as its possible interactions 
with protein residues. Because small-molecule natural products are made biosynthetically in nature 
by a particular enzyme, the imprint of interactions with proteins should be available from those 
synthetic enzymes, and, when deciphered, could be used to identify other target proteins for this 
specific natural product (Breinbauer et al., 2002; Kellenberger et al., 2011).
An important application for this approach lies in the prediction of off-targets for an individual 
ligand, as demonstrated by an inverse approach that identified the mycobacterial enoyl-acyl carrier 
protein reductase as a target for human catechol-O-methyl transferase inhibitors (Kinnings et al., 
2009) and screened for staurosporine recognition in a library of some 6400 protein ligand binding 
sites (Defranchi et al., 2010). Those studies demonstrated that the concepts applied in inverse 
screening may not necessarily apply the same protocols as conventional screening. In both cases, 
the screening protocols did not employ an atomic approach, but represented the protein binding 
sites as abstract objects consisting of the 3D coordinates of the Ca atoms and select 
physicochemical and geometrical properties. This concept has been embraced by the more recently 
proposed protein fold topology (McArdle et al., 2006), but to date, only few examples of such 
topologies have been established, mainly because the current computational methods do not 
adequately address the complex issue of fold similarity, as opposed to fold identity (for a review see 
(Kellenberger et al., 2011)).
At the same time, the methodology of inverse virtual screening based on conventional (all-atom) 
docking protocols was quickly expanded to test libraries of compounds against a panel of target 
proteins in order to evaluate the binding mode of several specific compounds (small compound 
libraries with 20-300 molecules) in order to achieve a reduction of cost and time requirement of a 
drug discovery project. However, while this approach is conceptually simple, the building of the 
panel of target proteins represents a critical step, because the targets must be carefully chosen if 
they do not belong to the same fold. Furthermore, analysis of the results is challenging and some 
elaborate post-processing strategies have been proposed (Lauro et al., 2011).
2.4 Expanding inverse virtual screening to larger compound libraries
In the present study, we sought to investigate the potential of inverse virtual screening in the 
identification of lead compounds from a moderately sized library (>1000 molecules) to reduce 
synthetic efforts and thus the costs of compound development and biological screening. Combined 
into this effort, we also explored the feasibility of novel N-heteroaryl imidazoline scaffolds as 
protein kinase inhibitors. Protein kinases are ideal targets for the inverse virtual screening approach, 
since they comprise a panel of proteins that adopt a conserved general fold, and features such as the 
nucleotide binding site of individual kinases are structurally highly similar. Our belief that the 
identification of new chemotypes for protein kinases may be facilitated by IVS was bolstered by 
two recent reports in which this approach was employed to identify specific kinase targets from 
large panels using 3 and 10 ligands, respectively (Lauro et al., 2012; Zahler et al., 2007).
In particular, we explored whether it was possible to overcome the limitations of docking in 
predicting functional molecules by using a statistical approach that removes aspects of 
“individuality” from the predicted hits. Such a statistical approach would, in principle, allow the in 
silico screening and scoring of a focussed virtual library in excess of 1000 members, 1-2 orders of 
magnitude larger than any reports to date. By making use of the many experimental three-
dimensional structures of kinases and docking the small-molecule library into multiple targets (i.e. 
panel docking), less emphasis is placed on  individual docking hits, and the overall performance of 
a particular compound against kinases is evaluated. The hypothesis is that compounds which 
frequently score highly may be more likely to possess biological activity. Synthetic efforts would 
then be reduced to a small diverse set of the top scoring compounds in panel docking, and it was 
hoped that this would provide fast access to novel biologically active molecules.
3. Towards a next-generation approach
3.1 Novel chemotypes for kinase drug discovery
Addressing the need for novel chemical scaffolds in protein kinase drug discovery, we generated a 
reasonable sized virtual library of compounds, based on synthetically feasible combinations of (i) 
two imidazoline moieties attached to different azine cores, including symmetrical  and non-
symmetrical topologies, as well as (ii) combinations of an imidazoline moiety and a primary or 
secondary amine attached to varying central azine cores.
Considering the focus on 2-aminoazine and -azole scaffolds of current kinase inhibitor discovery, 
the structural core of the N-heterocycle allows variations such as 2-pyridyl, 2-pyrazinyl, 2-
pyrimidinyl, and 4-pyrimidinyl and thus offers exploration of chemical scaffolds outside the 
previously explored chemical space. In particular, bis-imidazolinyl azines such as 1 present an 
intriguing novel kinase inhibitor scaffold to increase selectivity, whereby one 2-imidazolinylazine 
moiety could serve as a transient Hinge segment binder while the other contributed additional 
interactions with the protein target (see Figure 2A).
A motivating factor in the design of this library was thus to interrogate chemistry space beyond 
established 2-aminoazine and -azole motifs. To this end, a non-classical motif based on an N-
heteroaryl substituted 2-imidazoline, which we hypothesised may be particularly suited for binding 
to the protein kinase Hinge segments, was investigated. The 2-imidazoline moiety holds some 
promise as a novel scaffold for protein kinases as it possesses high solubility in aqueous 
environment (Remko et al., 2006) and, based on the reported broad range of biological activities 
against unrelated targets (Favaloro et al., 2003; Ferretti et al., 2002; Guo et al., 2008; Hong et al., 
2005; Kahlon et al., 2009; Li & Zhang, 2011), can also be considered a privileged structure (Evans 
et al., 1988). Exploiting privileged structures with drug-like properties has been a popular approach 
to drug discovery, particularly within the pharmaceutical industry. The term was originally 
introduced (Evans et al., 1988) to describe motifs that could be elaborated into libraries of drug-like 
molecules (ligands) in which different members could selectively and potently interact with a 
variety of unrelated biological targets.
The design of this focussed library of 1235 small molecules (library MK1235; see Supplemental 
Procedures S1) was thus based on central di-nitrogen heterocyclic moieties, including pyrazine, 
pyrimidine and pyridine, and motivated by two main criteria. First, access to novel 2-imidazoline 
N-heteroarylation chemistry was recently secured (Krasavin, 2012) and, second, N-heteroaryl-2-
imidazoline motifs such as 2 may become protonated in aqueous medium (see Figure 2B), and we 
speculate that the resulting chemotype 3 may be binding to the Hinge segment of protein kinases in 
a non-classical fashion. Intriguingly, the binding pose obtained for one of the successful compounds 
in this case study (9) supports this notion (Figure 2D). The library was additionally populated with 
N-heteroaryl mono imidazolines 4 and 5 (see Figure 2C) where the azine periphery can be 
decorated with a simple secondary and primary amine (in lieu of the second imidazoline moiety in 
1). Such compounds, even in the absence of strong predicted kinase binding scores and 
experimentally measured kinase inhibition potency, could at least serve as a reference set and help 
reveal the unique value of the bis-imidazoline skeletons 1 as a hitherto undescribed scaffold for 
kinase inhibitor design. In consideration of decorating groups, care was taken to achieve sufficient 
diversity that enables conclusions as to structure-activity relationships. 
3.2 Panel docking
Experimentally determined three-dimensional structures of kinase domains were retrieved from the 
PDB. The models were visually inspected for bound ligands (see Table 1), positioned and oriented 
with respect to a reference kinase domain, and all non-protein components were removed from the 
models. The library of 55 individual structures comprises 48 different kinases (see Supplemental 
Table S5).
In silico screening of the MK1235 library against the ATP-binding site of 55 structures from a 
kinase panel was conducted using AutoDock Vina (see Supplemental Procedures S2). The resulting 
scores were analysed by histogram analyses (Supplemental Figures S6 and S7) that considered the 
top five scored compounds for any kinase, based on the average score of each ligand for the 
predicted poses per individual kinase. From this histogram, 106 compounds were identified and 
subjected to cluster analysis to allow grouping based on Tanimoto similarity. Clustering was 
performed for both the “average score”  and “highest score”  docking selections (Supplemental 
Figure S8). Since the results based on the “average score” were found to generate more structurally 
dissimilar clusters on visual inspection, it was this clustering strategy that was used in the final 
nomination of the specific clusters for further study. The resulting 19 clusters with a population of 
>5 were appraised and the final five compounds (6-10) selected (Figure 3) that (i) represent their 
clusters, and (ii) provide a broad variety of different chemotypes (see Supplemental Figure S9).
3.3 In vitro kinase inhibition
Chemical synthesis of the selected compounds 6-10 required generation of imidazolines (Krasavin, 
2012) that were coupled with aryl halides using the Buchwald-Hartwig reaction (Guram et al., 
1995; Louie & Hartwig, 1995). For full details, as well as characterisation data, see Supplemental 
Procedures S3. The five compounds were then subjected to inhibition assays, using a panel of 48 
kinases provided by Cerep (see Supplemental Procedures S4). Assays were also conducted in the 
presence of a specific inhibitor for each individual kinase, and the inhibition data of the five novel 
compounds were compared to the inhibition elicited by the control compounds. Final results were 
expressed as percentage inhibition relative to a control (see Figure 4). Instances where at least 30% 
inhibition compared to the control experiment were achieved, were considered as promising, and 
observed for six compound/kinase pairs: CDK1:10, CDK2:10, IRK:6, Src kinase:9, TAOK2:10, 
TRKA:9. Notably, two of the five compounds, 7 and 8, could be excluded from the further work 
stream at this stage, as they only achieved a maximum of ~15% (7) and ~20% (8) inhibition as 
compared to control values.
For the six kinase-compound pairs identified above, dose-response data were then acquired (also at 
Cerep, France) in order to evaluate the IC50 values of the novel molecules (see Figure 5). Two of the 
three compounds tested at this stage, showed reasonable efficacy with IC50 values of around 14 mM 
(9 and 10). The third compound, 6, possessed only a low effect (IC50 = 0.1 mM).
4. Conclusion
Computational docking as a means to prioritise small molecules in drug discovery projects remains 
a highly popular in silico screening approach, despite its main shortcoming which is the general 
lack of a correlation  between docking scores and biological activity.
Here, we investigated the possibility to improve the selection of small molecule compounds for a 
drug discovery project by computationally screening ligands from a virtual library comprised of N-
heteroaryl-2-imidazoline derivatives against a panel of 48 mostly human kinases; the scheme shown 
in Figure 6 summarises this approach. In light of the exhaustion of the classical chemotypes of 
kinase inhibitors, the fundamentally new imidazolinyl azine chemotype is introduced here as 
promising starting point for kinase inhibitor design. Histogram analyses of the number of highest 
scoring compounds in the docking calculations were used to identify ~100 top scoring compounds. 
Subsequent grouping into clusters of maximal diversity enabled the selection of one representative 
each from five groups, which were synthesised and tested in kinase inhibition assays, with two of 
the five synthesised compounds achieving micro-molar inhibition in five human kinases.
In contrast to earlier inverse virtual screening approaches, where substantial numbers of compounds 
(26-265) needed to be synthesised (Muller et al., 2006; Urich et al., 2013), we present a case study 
of a highly economic and cost-effective pathway to the first lead molecules by putting less emphasis 
on the individual predicted docking poses but exploiting the statistical hit frequency. By 
synthesising just five compounds which were selected based on the results from panel docking, two 
compounds (9 and 10) with micro-molar IC50 values were identified from the original library of 
1235 members. These results also provide evidence that novel mono- and bis-imidazolinyl azines 
can serve as valid starting points for kinase inhibitor design.
Clearly, the panel docking approach as evaluated here does not abolish the need for a more rigorous 
prediction, or indeed experimental determination, of the binding pose of an individual ligand. The 
individual docking procedures in this survey have been carried out with conventional and widely 
used algorithms and scoring functions of AutoDock, and are thus subject to the inherent limitations 
of this methodology. Further more, in the analysis of the panel docking results, no attention is being 
paid to the individual binding pose of a ligand, but rather its ability to achieve many highly scored 
poses with different protein targets in the panel. We hypothesised that this might offer a new 
pathway to shortlist ligands from an initial library for synthesis in a drug discovery project. The 
results from this case study demonstrate that this methodology holds great promise for drug 
discovery projects  in cases where a group of target proteins share high structural similarity in their 
binding sites. The methodology described here might provide a means of improving the efficiency 
and cost-effectiveness of target and lead identification. Since the concept of panel docking is reliant 
on a high degree of similarity in the structural fold of the target, the method should also be 
applicable to other target classes, such as serine/threonine phosphatases which have recently 
emerged as novel targets in the fight against parasitism (Campbell et al., 2011).
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Table 1. Appraisal and preparation of kinase domains with known three-dimensional structures for 
panel docking in this study.
No of structures
Site of ligand Total Used
ATP-binding site 43 38
ATP-binding site and back pocket 6 6
ATP-binding site and other 1 1
ATP-binding site and substrate binding site 7 6
Substrate binding site 3 2
Other 1 1
None 8 4
Total 69 58
Figure legends
Figure 1
Illustration of fold and important structural elements of eukaryotic protein kinases, using protein 
kinase A as a representative example. The N-terminal lobe is coloured pale blue, and the C-terminal 
lobe is shown in pale brown. Residue side chains of the catalytic triad are rendered as stick models. 
The C-helix is coloured magenta, the activation loop is blue, the Hinge (Gly-rich loop) is orange, 
and the C-terminal tail is shown in pale red.
ATP binding in the nucleotide binding site between the Hinge and catalytic triad causes a clockwise 
rotation of the C-terminal tail, thus compacting the binding site and stabilising inter-lobe contacts 
(Andersen et al., 2001). Figure prepared with PyMOL (DeLano, 2002).
Figure 2
A Bis-imidazolinyl azines may provide additional sites of interaction with target kinases.
B Protonation of N-heteroaryl-2-imidazoline motifs may enable binding to the Hinge segment of 
protein kinases in a non-classical fashion.
C N-heteroaryl mono imidazolines were included in the library in this study and, in the absence of 
inhibitory potency, may be used as probes. 
D The binding poses of bis-imidazolinyl azines and N-heteroaryl mono imidazolines obtained in the 
docking calculations support the hypothesised unique interaction features of these chemotypes. 
Shown is the binding pose of 9 obtained with TRKA (PDB accession code 4aoj); the dashed lines 
indicate polar interactions with distances <3.8 Å. The functionalisation of 1 with a benzyl moiety on 
R appears to be an added benefit of compound 9, as this group is engaged in hydrophobic 
interactions with Phe251 of TRKA.
Figure 3
Compounds synthesised and tested, based on results from panel docking in this study. Compounds 
6-10 represent the clusters of molecules shown in Supplemental Figures S8, S9.
Figure 4
Results of inhibition assays for each of the compounds 6-10 against 48 kinases. Every increment on 
the x-axis represents an individual kinase. For compounds 6, 9 and 10, inhibition of more than 30% 
was achieved for the kinases labelled.
Figure 5
Dose-response data for six kinase-compound pairs at five different compound concentrations (0.3 
mM, 3 mM, 10 mM, 30 mM, 0.1 mM). Data points represent the average of two technical replica. The 
IC50 values for the pairings Src:9, TRKA:9, CDK1:10, CDK2:10, TAOK2:10 are around 14 mM.
Figure 6
Schematic comparison of conventional single docking and the panel docking methodology applied 
in this study.
Schematic comparison of conventional single docking and the panel docking methodology applied 
in this study. 
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